Literature DB >> 7168796

Cancer survival corrected for heterogeneity in patient withdrawal.

T Hakulinen.   

Abstract

Survival from cancer over a certain time period is often measured by the 'relative survival rate'. This is the ratio of the observed survival rate in the group of patients to the survival rate expected in a group of people in the general population, who are similar to the patients with respect to all of the possible factors affecting survival at the beginning of the period, except for the disease under study. When patterns of patient withdrawal differ for a number of subgroups of patients with equal relative survival rates, the current method of derivation of the relative survival rate is biased. A method based on the concept of an 'expected life table' is proposed for removal of the bias. Examples based on material from the Finnish Cancer Registry suggest that the practical performance of the proposed method is better than that of other alternatives, even when the relative survival rates in the subgroups are not equal.

Entities:  

Mesh:

Year:  1982        PMID: 7168796

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  70 in total

1.  German cancer statistics 2004.

Authors:  Jörg Haberland; Joachim Bertz; Ute Wolf; Thomas Ziese; Bärbel-Maria Kurth
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

2.  Cancer survival in adult patients in Spain. Results from nine population-based cancer registries.

Authors:  M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez
Journal:  Clin Transl Oncol       Date:  2017-07-17       Impact factor: 3.405

3.  Trends in cancer incidence, survival and mortality in northern Sweden 1960-1986.

Authors:  P Lenner; H Jonsson; O Gardfjell
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

4.  Secular trends in colon and rectal cancer relative survival.

Authors:  Carolyn M Rutter; Eric A Johnson; Eric J Feuer; Amy B Knudsen; Karen M Kuntz; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2013-10-30       Impact factor: 13.506

5.  Changes in long term prognosis for breast cancer in a Dutch cancer registry.

Authors:  H W Nab; W C Hop; M A Crommelin; H M Kluck; L H van der Heijden; J W Coebergh
Journal:  BMJ       Date:  1994-07-09

6.  Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Therese M-L Andersson; Sandra Eloranta; Paul W Dickman; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

7.  Emergency presentation of node-negative colorectal cancer treated with curative surgery is associated with poorer short and longer-term survival.

Authors:  Raymond Oliphant; David Mansouri; Gary A Nicholson; Donald C McMillan; Paul G Horgan; David S Morrison
Journal:  Int J Colorectal Dis       Date:  2014-03-22       Impact factor: 2.571

Review 8.  Long-term survival of cancer patients compared to heart failure and stroke: a systematic review.

Authors:  Vasileios Askoxylakis; Christian Thieke; Sven T Pleger; Patrick Most; Judith Tanner; Katja Lindel; Hugo A Katus; Jürgen Debus; Marc Bischof
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

9.  Establishing a follow-up of the Swiss MONICA participants (1984-1993): record linkage with census and mortality data.

Authors:  Matthias Bopp; Julia Braun; David Faeh; Felix Gutzwiller
Journal:  BMC Public Health       Date:  2010-09-21       Impact factor: 3.295

10.  Methodological issues in estimating survival in patients with multiple primary cancers: an application to women with breast cancer as a first tumour.

Authors:  Stefano Rosso; Fulvio Ricceri; Lea Terracini; Roberto Zanetti
Journal:  Emerg Themes Epidemiol       Date:  2009-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.